Marshall Wace
NTLA icon

Marshall Wace’s Intellia Therapeutics NTLA Stock Holding History

Marshall Wace’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.78M Buy
164,078
+26,653
+19% +$373K ﹤0.01% 1666
2026
Q1 		$1.76M Buy
+137,425
New +$1.75M ﹤0.01% 1857
2025
Q1 		– Sell
-95,339
Closed -$1.11M – 2951
2024
Q4 		$1.11M Buy
+95,339
New +$1.49M ﹤0.01% 1687
2024
Q2 		– Sell
-335,408
Closed -$9.23M – 2827
2024
Q1 		$9.23M Sell
335,408
-555,090
-62% -$15.4M 0.01% 774
2023
Q4 		$27.2M Buy
+890,498
New +$25.6M 0.05% 387
2023
Q1 		– Sell
-389,074
Closed -$13.6M – 2969
2022
Q4 		$13.6M Buy
389,074
+381,674
+5,158% +$18.1M 0.03% 641
2022
Q3 		$414K Sell
7,400
-2,724
-27% -$169K ﹤0.01% 2809
2022
Q2 		$524K Sell
10,124
-96,192
-90% -$4.88M ﹤0.01% 2770
2022
Q1 		$7.73M Buy
+106,316
New +$9.01M 0.01% 1059
2021
Q3 		– Sell
-74,744
Closed -$12.1M – 3296
2021
Q2 		$12.1M Buy
74,744
+59,835
+401% +$4.66M 0.05% 394
2021
Q1 		$1.2M Buy
14,909
+1,443
+11% +$96.9K 0.01% 1573
2020
Q4 		$733K Buy
+13,466
New +$489K ﹤0.01% 1329
2016
Q3 		– Sell
-11,408
Closed -$244K – 1073
2016
Q2 		$244K Buy
+11,408
New +$304K ﹤0.01% 921

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Marshall Wace's NTLA Position: Q2 2026 in Review

Marshall Wace increased its Intellia Therapeutics (NTLA) stake by 19% in Q2 2026, buying an estimated $373K and bringing the position to 164,078 shares worth $2.78M. The position accounts for ﹤0.01% of the portfolio, ranked #1666.

Marshall Wace first reported a position in NTLA in Q2 2016 and has held it in 13 quarters since. The position peaked at $27.2M in Q4 2023. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Marshall Wace held 164,078 shares of Intellia Therapeutics worth $2.78M as of Q2 2026.
  • Marshall Wace bought 26,653 Intellia Therapeutics shares in Q2 2026, an estimated $373K.
  • Intellia Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1666 holding.
  • Marshall Wace first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 13 quarters since.
  • Marshall Wace's Intellia Therapeutics position peaked at $27.2M in Q4 2023.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.